I sjældne tilfælde er dette også set ved behandling med angiotensin II- receptorantagonister, herunder telmisartan.
Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors, and with angiotensin II receptor antagonists, including telmisartan.